Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí sinh học Journal of Biology đề tài: Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma | Genetic Vaccines and Therapy BioMed Central Research Open Access Chitosan IFN-Y-pDNA Nanoparticle CIN Therapy for Allergic Asthma Mukesh Kumar Xiaoyuan Kong Aruna K Behera Gary R Hellermann Richard F Lockey and Shyam S Mohapatra Address The Joy McCann Culverhouse Airway Disease Center Division of Allergy and Immunology University of South Florida College of Medicine and James A Haley VA Hospital Tampa FL USA Email Mukesh Kumar - mkumar@ Xiaoyuan Kong - xkong@ Aruna K Behera - abehera@ Gary R Hellermann - ghellerm@ Richard F Lockey - rlockey@ Shyam S Mohapatra - smohapat@ Corresponding author Published 27 October 2003 Received 23 September 2003 Accepted 27 October 2003 Genetic Vaccines and Therapy 2003 1 3 This article is available from http content 1 1 3 2003 Kumar et al licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Background Allergic subjects produce relatively low amounts of IFN-Y a pleiotropic Th-1 cytokine that downregulates Th2-associated airway inflammation and hyperresponsiveness AHR the hallmarks of allergic asthma. Adenovirus-mediated IFN-Y gene transfer reduces AHR Th2 cytokine levels and lung inflammation in mice but its use would be limited by the frequency of gene delivery required therefore we tested chitosan IFN-Y pDNA nanoparticles CIN for in situ production of IFN-Y and its in vivo effects. Methods CIN were administered to OVA-sensitized mice to investigate the possibility of using gene transfer to modulate ovalbumin OVA -induced inflammation and AHR. Results Mice treated with CIN exhibit significantly lower AHR to methacholine challenge and less lung histopathology. Production of IFN-Y is increased after CIN treatment while the Th2-cytokines IL-4 and IL-5 and OVA-specific .
